Details of the Drug

General Information of Drug (ID: DM2NLS9)

Drug Name
Ciprofloxacin XR
Synonyms
ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Gram-positive bacterial infection 1B74-1G40 Approved [2]
Cystic fibrosis CA25 Phase 2 [3]
Biliary cancer 2E92.7 Phase 1 [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 331.34
Topological Polar Surface Area (xlogp) -1.1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [5]
Bioavailability
The bioavailability of drug is 45% [6]
Clearance
The renal clearance of drug is 5.08 mL/min/kg [7]
Elimination
27% of an oral dose was recovered unmetabolized in urine compared to 46% of an intravenous dose [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 hours [7]
Metabolism
The drug is metabolized via the CYP1A2 [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 34.4909 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.7% [10]
Vd
The volume of distribution (Vd) of drug is 0.161 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.15 mg/mL [5]
Chemical Identifiers
Formula
C17H18FN3O3
IUPAC Name
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
Canonical SMILES
C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
InChI
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
InChIKey
MYSWGUAQZAJSOK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2764
ChEBI ID
CHEBI:100241
CAS Number
85721-33-1
DrugBank ID
DB00537
TTD ID
D0O1WX
VARIDT ID
DR00783
INTEDE ID
DR2273
ACDINA ID
D00132

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [11], [12]
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Inhibitor [2]
Candida Thymidylate synthase (Candi TMP1) TTU6BFZ TYSY_CANAL Inhibitor [13]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [11], [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [14]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [15]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [16]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ciprofloxacin XR
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Clarithromycin. Bacterial infection [1A00-1C4Z] [79]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [79]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lomefloxacin. Bacterial infection [1A00-1C4Z] [79]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Telithromycin. Bacterial infection [1A00-1C4Z] [79]
Coadministration of a Drug Treating the Disease Different from Ciprofloxacin XR (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Ciprofloxacin XR caused by Sodium bicarbonate mediated altered urine pH. Acidosis [5C73] [80]
Tretinoin DM49DUI Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Tretinoin. Acne vulgaris [ED80] [81]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Ivosidenib. Acute myeloid leukaemia [2A60] [82]
Uracil mustard DMHL7OB Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Uracil mustard. Acute myeloid leukaemia [2A60] [81]
Midostaurin DMI6E0R Moderate Decreased metabolism of Ciprofloxacin XR caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [83]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Idarubicin. Acute myeloid leukaemia [2A60] [79]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Daunorubicin. Acute myeloid leukaemia [2A60] [79]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Arn-509. Acute myeloid leukaemia [2A60] [84]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Gilteritinib. Acute myeloid leukaemia [2A60] [85]
Oliceridine DM6MDCF Major Decreased metabolism of Ciprofloxacin XR caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [86]
Magnesium Sulfate DMVEK07 Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Magnesium Sulfate. Acute pain [MG31] [87]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Galantamine. Alzheimer disease [8A20] [79]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Rivastigmine. Alzheimer disease [8A20] [79]
Donepezil DMIYG7Z Minor Decreased metabolism of Ciprofloxacin XR caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [88]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Metronidazole. Amoebiasis [1A36] [89]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Ivabradine. Angina pectoris [BA40] [84]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Bepridil. Angina pectoris [BA40] [90]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Dronedarone. Angina pectoris [BA40] [79]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [91]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [79]
Cilostazol DMZMSCT Moderate Decreased metabolism of Ciprofloxacin XR caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [92]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Voriconazole. Aspergillosis [1F20] [79]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Posaconazole. Aspergillosis [1F20] [79]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Levalbuterol. Asthma [CA23] [93]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Terbutaline. Asthma [CA23] [94]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Pirbuterol. Asthma [CA23] [94]
Budesonide DMJIBAW Moderate Decreased metabolism of Ciprofloxacin XR caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [95]
Aminophylline DML2NIB Major Decreased metabolism of Ciprofloxacin XR caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [96]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Salbutamol. Asthma [CA23] [93]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Ciprofloxacin XR caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [84]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Formoterol. Asthma [CA23] [94]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [84]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Desipramine. Attention deficit hyperactivity disorder [6A05] [79]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Retigabine. Behcet disease [4A62] [79]
Cariprazine DMJYDVK Moderate Decreased metabolism of Ciprofloxacin XR caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [97]
Pexidartinib DMS2J0Z Major Decreased metabolism of Ciprofloxacin XR caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [98]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Loperamide. Bowel habit change [ME05] [99]
Temozolomide DMKECZD Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Temozolomide. Brain cancer [2A00] [81]
Lomustine DMMWSUL Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [81]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Eribulin. Breast cancer [2C60-2C6Y] [79]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lapatinib. Breast cancer [2C60-2C6Y] [79]
HKI-272 DM6QOVN Major Decreased metabolism of Ciprofloxacin XR caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [100]
LY2835219 DM93VBZ Moderate Decreased metabolism of Ciprofloxacin XR caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [101]
Palbociclib DMD7L94 Moderate Decreased metabolism of Ciprofloxacin XR caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Thiotepa DMIZKOP Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [81]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Tamoxifen. Breast cancer [2C60-2C6Y] [79]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Ciprofloxacin XR caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [102]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Toremifene. Breast cancer [2C60-2C6Y] [79]
Bosutinib DMTI8YE Major Decreased metabolism of Ciprofloxacin XR caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [89]
Atorvastatin DMF28YC Moderate Decreased metabolism of Ciprofloxacin XR caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [103]
Macitentan DMP79A1 Moderate Decreased metabolism of Ciprofloxacin XR caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [104]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [105]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Olodaterol. Chronic obstructive pulmonary disease [CA22] [94]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Vilanterol. Chronic obstructive pulmonary disease [CA22] [93]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Salmeterol. Chronic obstructive pulmonary disease [CA22] [94]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Indacaterol. Chronic obstructive pulmonary disease [CA22] [94]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Arformoterol. Chronic obstructive pulmonary disease [CA22] [94]
Phenylbutazone DMAYL0T Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Phenylbutazone. Chronic pain [MG30] [106]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Ketoprofen. Chronic pain [MG30] [106]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Ciprofloxacin XR caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [79]
Capecitabine DMTS85L Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [81]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Isoproterenol. Conduction disorder [BC63] [93]
Mestranol DMG3F94 Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [107]
Levobupivacaine DM783CH Moderate Decreased metabolism of Ciprofloxacin XR caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [84]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Halothane. Corneal disease [9A76-9A78] [79]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Propofol. Corneal disease [9A76-9A78] [108]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Sevoflurane. Corneal disease [9A76-9A78] [79]
Alfentanil DMVO0UB Moderate Decreased metabolism of Ciprofloxacin XR caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [109]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Probucol. Coronary atherosclerosis [BA80] [79]
Oxtriphylline DMLHSE3 Major Decreased metabolism of Ciprofloxacin XR caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [96]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Mifepristone. Cushing syndrome [5A70] [79]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Pasireotide. Cushing syndrome [5A70] [79]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Osilodrostat. Cushing syndrome [5A70] [84]
Aprepitant DM053KT Moderate Decreased metabolism of Ciprofloxacin XR caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [110]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Trimipramine. Depression [6A70-6A7Z] [79]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Nortriptyline. Depression [6A70-6A7Z] [79]
Vilazodone DM4LECQ Moderate Decreased metabolism of Ciprofloxacin XR caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [111]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Escitalopram. Depression [6A70-6A7Z] [79]
OPC-34712 DMHG57U Major Decreased metabolism of Ciprofloxacin XR caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [112]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Clomipramine. Depression [6A70-6A7Z] [79]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Trazodone. Depression [6A70-6A7Z] [113]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Amoxapine. Depression [6A70-6A7Z] [79]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Doxepin. Depression [6A70-6A7Z] [79]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Maprotiline. Depression [6A70-6A7Z] [79]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Ciprofloxacin XR caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [114]
PMID28870136-Compound-49 DMTUC9E Moderate Decreased metabolism of Ciprofloxacin XR caused by PMID28870136-Compound-49 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [115]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [79]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Deutetrabenazine. Dystonic disorder [8A02] [116]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Ingrezza. Dystonic disorder [8A02] [117]
Diazepam DM08E9O Minor Decreased metabolism of Ciprofloxacin XR caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [118]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Ciprofloxacin XR caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [119]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ciprofloxacin XR caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Cannabidiol DM0659E Minor Decreased metabolism of Ciprofloxacin XR caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [84]
Mefenamic acid DMK7HFI Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Mefenamic acid. Female pelvic pain [GA34] [106]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Ciprofloxacin XR caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [120]
Tazemetostat DMWP1BH Major Decreased metabolism of Ciprofloxacin XR caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [121]
Solifenacin DMG592Q Moderate Decreased metabolism of Ciprofloxacin XR caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [122]
Mirabegron DMS1GYT Minor Decreased metabolism of Ciprofloxacin XR caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [123]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Ciprofloxacin XR caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [124]
Itraconazole DMCR1MV Moderate Decreased metabolism of Ciprofloxacin XR caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [125]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Pentamidine. Fungal infection [1F29-1F2F] [79]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Ketoconazole. Fungal infection [1F29-1F2F] [79]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Cisapride. Gastro-oesophageal reflux disease [DA22] [79]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Sunitinib. Gastrointestinal stromal tumour [2B5B] [79]
Avapritinib DMK2GZX Major Decreased metabolism of Ciprofloxacin XR caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [84]
Colchicine DM2POTE Major Decreased metabolism of Ciprofloxacin XR caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [126]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Ciprofloxacin XR caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [127]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Ciprofloxacin XR caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [89]
Procarbazine DMIK367 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [81]
MK-1439 DM215WE Minor Decreased metabolism of Ciprofloxacin XR caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [129]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [130]
Dolutegravir DMCZGRE Minor Decreased metabolism of Ciprofloxacin XR caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [131]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [132]
Didanosine DMI2QPE Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [133]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [79]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [79]
Maraviroc DMTL94F Moderate Decreased metabolism of Ciprofloxacin XR caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [134]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [135]
Simvastatin DM30SGU Moderate Decreased metabolism of Ciprofloxacin XR caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [103]
BMS-201038 DMQTAGO Major Decreased metabolism of Ciprofloxacin XR caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [89]
Aliskiren DM1BV7W Moderate Decreased metabolism of Ciprofloxacin XR caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [79]
Levamlodipine DM92S6N Moderate Decreased metabolism of Ciprofloxacin XR caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [79]
Quinapril DMR8H31 Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [84]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Ciprofloxacin XR caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [136]
Fludrocortisone DMUDIR8 Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [137]
Pirfenidone DM6VZFQ Major Decreased metabolism of Ciprofloxacin XR caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [84]
Retapamulin DM9JXB7 Minor Decreased metabolism of Ciprofloxacin XR caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [138]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Ciprofloxacin XR and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [89]
Meclofenamic acid DM05FXR Moderate Additive CNS stimulant effects by the combination of Ciprofloxacin XR and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [139]
Suvorexant DM0E6S3 Major Decreased metabolism of Ciprofloxacin XR caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [140]
Ramelteon DM7IW9J Moderate Decreased metabolism of Ciprofloxacin XR caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [141]
Melatonin DMKWFBT Minor Decreased metabolism of Ciprofloxacin XR caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [89]
Tasimelteon DMLOQ1V Major Decreased metabolism of Ciprofloxacin XR caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [142]
ITI-007 DMUQ1DO Major Decreased metabolism of Ciprofloxacin XR caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [143]
Iron DMAP8MV Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [144]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Ciprofloxacin XR and Polyethylene glycol. Irritable bowel syndrome [DD91] [79]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Phenolphthalein. Irritable bowel syndrome [DD91] [79]
Alosetron DML2A03 Moderate Decreased metabolism of Ciprofloxacin XR caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [145]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Ciprofloxacin XR caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [146]
Naloxegol DML0B41 Major Decreased metabolism of Ciprofloxacin XR caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [84]
Pemigatinib DM819JF Major Decreased metabolism of Ciprofloxacin XR caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [84]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Crizotinib. Lung cancer [2C25] [147]
Brigatinib DM7W94S Major Decreased metabolism of Ciprofloxacin XR caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [89]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Ciprofloxacin XR and Porfimer Sodium. Lung cancer [2C25] [148]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Ceritinib. Lung cancer [2C25] [79]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Ciprofloxacin XR caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [149]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Ciprofloxacin XR caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [150]
Osimertinib DMRJLAT Moderate Decreased metabolism of Ciprofloxacin XR caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [151]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Ciprofloxacin XR caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [152]
Capmatinib DMYCXKL Moderate Decreased metabolism of Ciprofloxacin XR caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [153]
Selpercatinib DMZR15V Major Decreased metabolism of Ciprofloxacin XR caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lumefantrine. Malaria [1F40-1F45] [89]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Halofantrine. Malaria [1F40-1F45] [154]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Chloroquine. Malaria [1F40-1F45] [155]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Hydroxychloroquine. Malaria [1F40-1F45] [155]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Primaquine. Malaria [1F40-1F45] [79]
Fludarabine DMVRLT7 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [81]
Pentostatin DM0HXDS Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Pentostatin. Mature B-cell leukaemia [2A82] [81]
Idelalisib DM602WT Moderate Decreased metabolism of Ciprofloxacin XR caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [156]
GDC-0199 DMH0QKA Major Decreased metabolism of Ciprofloxacin XR caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [89]
IPI-145 DMWA24P Moderate Decreased metabolism of Ciprofloxacin XR caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [157]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Arsenic trioxide. Mature B-cell lymphoma [2A85] [158]
Acalabrutinib DM7GCVW Major Decreased metabolism of Ciprofloxacin XR caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [159]
Clofarabine DMCVJ86 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Clofarabine. Mature B-cell lymphoma [2A85] [81]
Ibrutinib DMHZCPO Major Decreased metabolism of Ciprofloxacin XR caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [160]
Vincristine DMINOX3 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Vincristine. Mature B-cell lymphoma [2A85] [81]
Mercaptopurine DMTM2IK Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [81]
Ponatinib DMYGJQO Moderate Decreased metabolism of Ciprofloxacin XR caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [161]
Cytarabine DMZD5QR Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [81]
Mechlorethamine DM0CVXA Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Mechlorethamine. Mature T-cell lymphoma [2A90] [81]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Vemurafenib. Melanoma [2C30] [79]
Selumetinib DMC7W6R Major Decreased metabolism of Ciprofloxacin XR caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [162]
Dacarbazine DMNPZL4 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Dacarbazine. Melanoma [2C30] [81]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and LGX818. Melanoma [2C30] [163]
Ethinyl estradiol DMODJ40 Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Ethinyl estradiol. Menopausal disorder [GA30] [107]
Ubrogepant DM749I3 Moderate Decreased metabolism of Ciprofloxacin XR caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [164]
Rimegepant DMHOAUG Moderate Decreased metabolism of Ciprofloxacin XR caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [165]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Ciprofloxacin XR due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [79]
Flibanserin DM70DTN Major Decreased metabolism of Ciprofloxacin XR caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [166]
Riluzole DMECBWN Minor Decreased metabolism of Ciprofloxacin XR caused by Riluzole mediated inhibition of CYP450 enzyme. Motor neuron disease [8B60] [167]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Panobinostat. Multiple myeloma [2A83] [168]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Thalidomide. Multiple myeloma [2A83] [89]
Melphalan DMOLNHF Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [81]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Siponimod. Multiple sclerosis [8A40] [89]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Fingolimod. Multiple sclerosis [8A40] [79]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Ozanimod. Multiple sclerosis [8A40] [169]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Deflazacort. Muscular dystrophy [8C70] [137]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Ciprofloxacin XR and Methoxsalen. Mycosis fungoides [2B01] [89]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Romidepsin. Mycosis fungoides [2B01] [79]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Ciprofloxacin XR caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [84]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Nilotinib. Myeloproliferative neoplasm [2A20] [79]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Ciprofloxacin XR caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [84]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Dasatinib. Myeloproliferative neoplasm [2A20] [170]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [81]
Busulfan DMXYJ9C Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [81]
Modafinil DMYILBE Minor Decreased metabolism of Ciprofloxacin XR caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [89]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Promethazine. Nausea/vomiting [MD90] [79]
Metoclopramide DMFA5MY Minor Altered absorption of Ciprofloxacin XR due to GI dynamics variation caused by Metoclopramide. Nausea/vomiting [MD90] [171]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Granisetron. Nausea/vomiting [MD90] [79]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Dolasetron. Nausea/vomiting [MD90] [79]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Ondansetron. Nausea/vomiting [MD90] [79]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Ciprofloxacin XR and Bupropion. Nicotine use disorder [6C4A] [172]
Entrectinib DMMPTLH Major Decreased metabolism of Ciprofloxacin XR caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [89]
Sibutramine DMFJTDI Minor Decreased metabolism of Ciprofloxacin XR caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [173]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Levomethadyl Acetate. Opioid use disorder [6C43] [84]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lofexidine. Opioid use disorder [6C43] [79]
S-297995 DM26IH8 Moderate Decreased metabolism of Ciprofloxacin XR caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [84]
Valdecoxib DMAY7H4 Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Valdecoxib. Osteoarthritis [FA00-FA05] [106]
Diclofenac DMPIHLS Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Diclofenac. Osteoarthritis [FA00-FA05] [106]
Naproxen DMZ5RGV Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Naproxen. Osteoarthritis [FA00-FA05] [106]
Olaparib DM8QB1D Major Decreased metabolism of Ciprofloxacin XR caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [89]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Rucaparib. Ovarian cancer [2C73] [79]
Carboplatin DMG281S Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Carboplatin. Ovarian cancer [2C73] [81]
Topotecan DMP6G8T Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [81]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Dextropropoxyphene. Pain [MG30-MG3Z] [174]
Butorphanol DM5KYPJ Major Decreased metabolism of Ciprofloxacin XR caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [175]
Aspirin DM672AH Moderate Additive CNS stimulant effects by the combination of Ciprofloxacin XR and Aspirin. Pain [MG30-MG3Z] [176]
Etodolac DM6WJO9 Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Etodolac. Pain [MG30-MG3Z] [106]
Diflunisal DM7EN8I Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Diflunisal. Pain [MG30-MG3Z] [106]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Ibuprofen. Pain [MG30-MG3Z] [106]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Ciprofloxacin XR caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [177]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Ciprofloxacin XR caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [178]
Piroxicam DMTK234 Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Piroxicam. Pain [MG30-MG3Z] [106]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Triclabendazole. Parasitic worm infestation [1F90] [79]
Istradefylline DM20VSK Moderate Decreased metabolism of Ciprofloxacin XR caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [179]
Rasagiline DM3WKQ4 Major Decreased metabolism of Ciprofloxacin XR caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [89]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Pimavanserin. Parkinsonism [8A00] [180]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Apomorphine. Parkinsonism [8A00] [79]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Famotidine. Peptic ulcer [DA61] [89]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Macimorelin. Pituitary gland disorder [5A60-5A61] [181]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lefamulin. Pneumonia [CA40] [182]
Choline salicylate DM8P137 Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Choline salicylate. Postoperative inflammation [1A00-CA43] [106]
Hydrocortisone DMGEMB7 Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Hydrocortisone. Postoperative inflammation [1A00-CA43] [137]
Bromfenac DMKB79O Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Bromfenac. Postoperative inflammation [1A00-CA43] [106]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Ciprofloxacin XR caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [183]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Ciprofloxacin XR caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [184]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Ritodrine. Preterm labour/delivery [JB00] [94]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Degarelix. Prostate cancer [2C82] [84]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and ABIRATERONE. Prostate cancer [2C82] [84]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Nilutamide. Prostate cancer [2C82] [84]
Enzalutamide DMGL19D Moderate Decreased metabolism of Ciprofloxacin XR caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [185]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Relugolix. Prostate cancer [2C82] [84]
Darolutamide DMV7YFT Minor Decreased metabolism of Ciprofloxacin XR caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [186]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Bicalutamide. Prostate cancer [2C82] [84]
Silodosin DMJSBT6 Moderate Decreased metabolism of Ciprofloxacin XR caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [187]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Ciprofloxacin XR caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [188]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Levomepromazine. Psychotic disorder [6A20-6A25] [79]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Fluphenazine. Psychotic disorder [6A20-6A25] [79]
Bosentan DMIOGBU Moderate Decreased metabolism of Ciprofloxacin XR caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [189]
Axitinib DMGVH6N Moderate Decreased metabolism of Ciprofloxacin XR caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [84]
Temsirolimus DMS104F Moderate Decreased metabolism of Ciprofloxacin XR caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [190]
Salsalate DM13P4C Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Salsalate. Rheumatoid arthritis [FA20] [106]
Meloxicam DM2AR7L Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Meloxicam. Rheumatoid arthritis [FA20] [106]
Sulindac DM2QHZU Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Sulindac. Rheumatoid arthritis [FA20] [106]
Upadacitinib DM32B5U Moderate Decreased metabolism of Ciprofloxacin XR caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [191]
Oxaprozin DM9UB0P Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Oxaprozin. Rheumatoid arthritis [FA20] [106]
Tofacitinib DMBS370 Moderate Decreased metabolism of Ciprofloxacin XR caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [89]
Flurbiprofen DMGN4BY Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Flurbiprofen. Rheumatoid arthritis [FA20] [106]
Fenoprofen DML5VQ0 Moderate Additive CNS depression effects by the combination of Ciprofloxacin XR and Fenoprofen. Rheumatoid arthritis [FA20] [106]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Dexamethasone. Rheumatoid arthritis [FA20] [137]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Quetiapine. Schizophrenia [6A20] [79]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Mesoridazine. Schizophrenia [6A20] [79]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Thioridazine. Schizophrenia [6A20] [79]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Ciprofloxacin XR caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [192]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Iloperidone. Schizophrenia [6A20] [79]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Paliperidone. Schizophrenia [6A20] [79]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Perphenazine. Schizophrenia [6A20] [79]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Trifluoperazine. Schizophrenia [6A20] [79]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Risperidone. Schizophrenia [6A20] [79]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Amisulpride. Schizophrenia [6A20] [193]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Asenapine. Schizophrenia [6A20] [79]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Pimozide. Schizophrenia [6A20] [84]
Salicyclic acid DM2F8XZ Moderate Additive CNS stimulant effects by the combination of Ciprofloxacin XR and Salicyclic acid. Seborrhoeic dermatitis [EA81] [176]
Avanafil DM75CXN Major Decreased metabolism of Ciprofloxacin XR caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [194]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Ciprofloxacin XR caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [195]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Vardenafil. Sexual dysfunction [HA00-HA01] [79]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Ciprofloxacin XR caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [196]
LDE225 DMM9F25 Major Decreased metabolism of Ciprofloxacin XR caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [197]
Larotrectinib DM26CQR Moderate Decreased metabolism of Ciprofloxacin XR caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [89]
Dactinomycin DM2YGNW Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [81]
Methylprednisolone DM4BDON Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [137]
Vinblastine DM5TVS3 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Vinblastine. Solid tumour/cancer [2A00-2F9Z] [81]
Ifosfamide DMCT3I8 Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [81]
Docetaxel DMDI269 Moderate Decreased metabolism of Ciprofloxacin XR caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [198]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Ciprofloxacin XR caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Armodafinil DMGB035 Minor Decreased metabolism of Ciprofloxacin XR caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [89]
Mitoxantrone DMM39BF Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [81]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and LEE011. Solid tumour/cancer [2A00-2F9Z] [79]
Etoposide DMNH3PG Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Etoposide. Solid tumour/cancer [2A00-2F9Z] [81]
Prednisolone DMQ8FR2 Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [137]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [79]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [84]
Fluorouracil DMUM7HZ Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [81]
Taxol DMUOT9V Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [81]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [79]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Pitolisant. Somnolence [MG42] [79]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [79]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Ciprofloxacin XR and Adenosine. Supraventricular tachyarrhythmia [BC81] [79]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Ciprofloxacin XR caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [89]
Plicamycin DM7C8YV Minor Decreased absorption of Ciprofloxacin XR due to intestinal mucosa variation caused by Plicamycin. Testicular cancer [2C80] [81]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Ciprofloxacin XR caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [199]
Apixaban DM89JLN Moderate Decreased metabolism of Ciprofloxacin XR caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [84]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Lenvatinib. Thyroid cancer [2D10] [79]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Cabozantinib. Thyroid cancer [2D10] [84]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Papaverine. Tonus and reflex abnormality [MB47] [200]
Tizanidine DMR2IQ4 Major Decreased metabolism of Ciprofloxacin XR caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [201]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Ciprofloxacin XR due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [202]
Tacrolimus DMZ7XNQ Moderate Increased risk of nephrotoxicity by the combination of Ciprofloxacin XR and Tacrolimus. Transplant rejection [NE84] [89]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Ciprofloxacin XR and Plazomicin. Urinary tract infection [GC08] [89]
Elagolix DMB2C0E Moderate Decreased metabolism of Ciprofloxacin XR caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [203]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Astemizole. Vasomotor/allergic rhinitis [CA08] [79]
Triamcinolone DM98IXF Major Increased risk of tendinitis/tendon rupture by the combination of Ciprofloxacin XR and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [137]
Fluticasone DMGCSVF Moderate Decreased metabolism of Ciprofloxacin XR caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [89]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Procainamide. Ventricular tachyarrhythmia [BC71] [90]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Propafenone. Ventricular tachyarrhythmia [BC71] [79]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Flecainide. Ventricular tachyarrhythmia [BC71] [79]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Ciprofloxacin XR and Amiodarone. Ventricular tachyarrhythmia [BC71] [90]
⏷ Show the Full List of 318 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acetic acid E00002 176 Acidulant; Buffering agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Succinic acid E00044 1110 Buffering agent
Sunset yellow FCF E00255 17730 Colorant
Sodium acetate E00431 517045 Antimicrobial preservative; Buffering agent; Flavoring agent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Edetate disodium E00186 8759 Complexing agent
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ciprofloxacin 1000 mg tablet 1000 mg 24 HR Extended Release Oral Tablet Oral
Ciprofloxacin 500 mg tablet 500 mg 24 HR Extended Release Oral Tablet Oral
Ciprofloxacin Hydrochloride eq 100mg base tablet eq 100mg base Tablet Oral
Ciprofloxacin 250 mg tablet 250 mg Oral Tablet Oral
Ciprofloxacin 500 mg tablet 500 mg Oral Tablet Oral
Ciprofloxacin Hydrochloride eq 0.3% base solution eq 0.3% base Solution Ophthalmic
Ciprofloxacin 750 mg tablet 750 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
3 Inhaled Ciprofloxacin for the Management of Infections in Non-Cystic Fibrosis Bronchiectasis (BE) Patients
4 Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9.
5 BDDCS applied to over 900 drugs
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984 Aug;3(4):355-9.
8 FDA Approved Drug Products: CIPRO (ciprofloxacin) oral tablets and suspension
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 DOI: 10.1093/jac/48.4.479
13 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
14 Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother. 2009 Jun;53(6):2410-6.
15 Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
16 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
17 Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol. 2008 Jul;74(1):122-31.
18 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
19 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
20 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
21 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
22 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
23 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
24 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
25 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
26 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
27 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
28 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
29 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
30 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
31 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
32 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
33 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
34 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
35 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
36 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
37 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
38 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
39 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
40 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
41 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
42 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
43 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
44 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
45 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
46 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
47 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
48 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
49 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
50 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
51 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
52 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
53 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
54 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
55 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
56 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
57 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
58 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
59 Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
60 Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
61 Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
62 Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
63 Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
64 Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
65 Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
66 In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6.
67 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
68 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
69 The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
70 Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
71 Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
72 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
73 DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
74 Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
75 Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44.
76 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
77 A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
78 Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
79 Canadian Pharmacists Association.
80 Multum Information Services, Inc. Expert Review Panel.
81 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
82 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
83 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
84 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
85 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
86 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
87 Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
88 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
89 Cerner Multum, Inc. "Australian Product Information.".
90 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
91 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
92 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
93 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
94 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
95 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
96 Bachmann KA, Schwartz JI, Jauregui L "Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements." Br J Clin Pharmacol 26 (1988): 191-4. [PMID: 3207556]
97 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
98 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
99 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
100 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
101 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
102 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
103 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
104 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
105 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
106 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
107 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
108 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
109 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
110 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
111 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
112 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
113 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
114 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
115 Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol 61 (2006): 138-47. [PMID: 16433868]
116 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
117 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
118 Kamali F, Thomas SH, Edwards C "The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers." Eur J Clin Pharmacol 44 (1993): 365-7. [PMID: 8513847]
119 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
120 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
121 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
122 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
123 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
124 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
125 Product Information. Sporonox (itraconazole). Janssen Pharmaceutica, Titusville, NJ.
126 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
127 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
128 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
129 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
130 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
131 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
132 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
133 Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
134 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
135 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
136 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
137 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
138 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
139 Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
140 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
141 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
142 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
143 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
144 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
145 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
146 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
147 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
148 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
149 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
150 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
151 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
152 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
153 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
154 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
155 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
156 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
157 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
158 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
159 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
160 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
161 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
162 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
163 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
164 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
165 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
166 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
167 Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
168 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
169 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
170 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
171 Product Information. Cipro (ciprofloxacin). Bayer, West Haven, CT.
172 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
173 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
174 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
175 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
176 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
177 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
178 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
179 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
180 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
181 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
182 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
183 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
184 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
185 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
186 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
187 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
188 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
189 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
190 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
191 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
192 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
193 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
194 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
195 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
196 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
197 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
198 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
199 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
200 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
201 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
202 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
203 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.